title: MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
abstract: The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML.
authors.affiliation: Foundation for Applied Medical Research, Division of Cancer, Area of Cell Therapy and Hematology Service, Clínica Universitaria, Universidad de Navarra, Spain. esanjose@alumni.unav.es
authors.forename: Edurne
authors.initials: E
authors.lastname: San José-Enériz
authors.forename: José
authors.initials: J
authors.lastname: Román-Gómez
authors.forename: Antonio
authors.initials: A
authors.lastname: Jiménez-Velasco
authors.forename: Leire
authors.initials: L
authors.lastname: Garate
authors.forename: Vanesa
authors.initials: V
authors.lastname: Martin
authors.forename: Lucia
authors.initials: L
authors.lastname: Cordeu
authors.forename: Amaia
authors.initials: A
authors.lastname: Vilas-Zornoza
authors.forename: Paula
authors.initials: P
authors.lastname: Rodríguez-Otero
authors.forename: María José
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: Felipe
authors.initials: F
authors.lastname: Prósper
authors.forename: Xabier
authors.initials: X
authors.lastname: Agirre
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D016000:Cluster Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D020869:Gene Expression Profiling; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D035683:MicroRNAs / Q000235:genetics*; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D035683:MicroRNAs; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate